This makes TSLP a unique targeted biological therapy that could potentially be used for the treatment of CRLF2 B-ALL, either as part of a combination treatment regimen during maintenance therapy or to treat minimal residual disease (MRD) for the prevention of relapse. The gene discussed is TSLP; the disease is acute lymphoblastic leukemia.